3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
7
Active not recruiting
3
Withdrawn
2
Unknown
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Rectal Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Sarcoma
8
Stomach Neoplasms
7
Esophageal Neoplasms
7
Breast Neoplasms
7
Neoplasms
5
Lung Neoplasms
5
Hypopharyngeal Neoplasms
5
Carcinoma, Hepatocellular
5
Recurrence
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Oropharyngeal Neoplasms
4
Neoplasm Metastasis
4
Thyroid Neoplasms
3
Nasopharyngeal Carcinoma
3
Melanoma
3
Laryngeal Neoplasms
3
Head and Neck Neoplasms
3
Glioma
3
Glioblastoma
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Osteosarcoma
2
Mouth Neoplasms
2
Hyperthermia
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Interventions
Cisplatin
20
Radiotherapy
16
Paclitaxel
14
Carboplatin
12
pembrolizumab
11
Drug Therapy
11
tislelizumab
10
Fluorouracil
8
Neoadjuvant Therapy
7
130-nm albumin-bound paclitaxel
7
sintilimab
5
Esophagectomy
5
toripalimab
4
Tegafur
4
TP protocol
4
Nivolumab
4
Irinotecan
4
Immunotherapy
4
spartalizumab
3
S 1 (combination)
3
Oxaliplatin
3
Leucovorin
3
Itraconazole
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
nimotuzumab
2
apatinib
2
Taxes
2
Radiotherapy, Intensity-Modulated
2
Immune Checkpoint Inhibitors
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Esophageal Squamous Cell Carcinoma
×
Surgical Procedures, Operative
×
Clear all
NCT03964753
2023-10-10
NTNC
Hebei Medical University Fourth Hospital
Phase 2
Recruiting
202 enrolled